Cargando…

New treatment options for inflammatory bowel diseases

The advent of anti-TNF agents has dramatically changed the treatment algorithms for IBD in the last 15 years, but primarily and more importantly secondary loss of response is often observed. Fortunately , new treatment options have been actively explored and some have already entered our clinical pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Verstockt, Bram, Ferrante, Marc, Vermeire, Séverine, Van Assche, Gert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5910475/ https://www.ncbi.nlm.nih.gov/pubmed/29556726 http://dx.doi.org/10.1007/s00535-018-1449-z

Ejemplares similares

New biologics and small molecules in inflammatory bowel disease: an update
por: Sabino, João, et al.
Publicado: (2019)

Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease
por: Verstockt, Bram, et al.
Publicado: (2019)

Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases
por: Verstockt, Bram, et al.
Publicado: (2020)

Inflammatory Bowel Disease (IBD)—A Textbook Case for Multi-Centric Banking of Human Biological Materials
por: Cleynen, Isabelle, et al.
Publicado: (2019)

Effects of Epithelial IL-13Rα2 Expression in Inflammatory Bowel Disease
por: Verstockt, Bram, et al.
Publicado: (2018)

Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease
por: Verstockt, Sare, et al.
Publicado: (2021)

Vaccination and infection prevention in inflammatory bowel disease
por: Vermeire, Severine, et al.
Publicado: (2010)

Biological Therapy in Inflammatory Bowel Disease Patients Partly Restores Intestinal Innate Lymphoid Cell Subtype Equilibrium
por: Creyns, Brecht, et al.
Publicado: (2020)

Biomarker discovery for personalized therapy selection in inflammatory bowel diseases: Challenges and promises
por: Alsoud, Dahham, et al.
Publicado: (2022)

Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All
por: Sudhakar, Padhmanand, et al.
Publicado: (2022)

Mucosal IL13RA2 expression predicts nonresponse to anti‐TNF therapy in Crohn's disease
por: Verstockt, Bram, et al.
Publicado: (2019)

The Occurrence of Thrombosis in Inflammatory Bowel Disease Is Reflected in the Clot Lysis Profile
por: Bollen, Lize, et al.
Publicado: (2015)

Understanding the Molecular Drivers of Disease Heterogeneity in Crohn’s Disease Using Multi-omic Data Integration and Network Analysis
por: Sudhakar, Padhmanand, et al.
Publicado: (2020)

Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain?
por: Jacobs, Inge, et al.
Publicado: (2021)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
por: Verstockt, Bram, et al.
Publicado: (2023)

Integrated analysis of microbe-host interactions in Crohn’s disease reveals potential mechanisms of microbial proteins on host gene expression
por: Sudhakar, Padhmanand, et al.
Publicado: (2022)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Inhibition of gelatinase B/MMP-9 does not attenuate colitis in murine models of inflammatory bowel disease
por: de Bruyn, Magali, et al.
Publicado: (2017)

GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD
por: Dierckx, Tim, et al.
Publicado: (2019)

Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis
por: Lee, Ho-Su, et al.
Publicado: (2020)

Mucosal Gene Expression of Antimicrobial Peptides in Inflammatory Bowel Disease Before and After First Infliximab Treatment
por: Arijs, Ingrid, et al.
Publicado: (2009)

Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and Fcγ-Receptor Signaling Pathways
por: Prins, Marileen M., et al.
Publicado: (2021)

Infliximab: the evidence for its place in therapy in ulcerative colitis
por: Van Assche, Gert, et al.
Publicado: (2007)

Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon
por: Verstockt, Bram, et al.
Publicado: (2020)

Immunogenicity of biologics in inflammatory bowel disease
por: Vermeire, Séverine, et al.
Publicado: (2018)

Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer
por: Jauregui-Amezaga, Aranzazu, et al.
Publicado: (2016)

Microbiota, not host origin drives ex vivo intestinal epithelial responses
por: Arnauts, Kaline, et al.
Publicado: (2022)

Computational Biology and Machine Learning Approaches to Understand Mechanistic Microbiome-Host Interactions
por: Sudhakar, Padhmanand, et al.
Publicado: (2021)

Evaluation of serum cytokines and acute phase proteins as possible pharmacodynamic biomarkers to monitor endoscopic remission during ustekinumab therapy in patients with Crohn’s disease
por: Van den Berghe, Nathalie, et al.
Publicado: (2023)

Personalized Dietary Regimens for Inflammatory Bowel Disease: Current Knowledge and Future Perspectives
por: Wellens, Judith, et al.
Publicado: (2023)

Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation
por: Van Stappen, Thomas, et al.
Publicado: (2016)

Fibrogenesis in chronic murine colitis is independent of innate lymphoid cells
por: Creyns, Brecht, et al.
Publicado: (2020)

Multi‐model averaging improves the performance of model‐guided infliximab dosing in patients with inflammatory bowel diseases
por: Kantasiripitak, Wannee, et al.
Publicado: (2022)

How to place the duality of specific MMP-9 inhibition for treatment of inflammatory bowel diseases into clinical opportunities?
por: Opdenakker, Ghislain, et al.
Publicado: (2022)

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
por: Pouillon, Lieven, et al.
Publicado: (2019)

Fibrogenesis in Chronic DSS Colitis is Not Influenced by Neutralisation of Regulatory T Cells, of Major T Helper Cytokines or Absence of IL-13
por: Creyns, Brecht, et al.
Publicado: (2019)

Emerging therapeutic options in inflammatory bowel disease
por: Yamamoto-Furusho, Jesus K, et al.
Publicado: (2021)

Big data in IBD: big progress for clinical practice
por: Seyed Tabib, Nasim Sadat, et al.
Publicado: (2020)

An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians’ Perspective
por: Schmidt, Carsten, et al.
Publicado: (2021)

What are the Unmet Needs and Most Relevant Treatment Outcomes According to Patients with Inflammatory Bowel Disease? A Qualitative Patient Preference Study
por: Schoefs, Elise, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_csvbn66g2cvas55gmktk2o5sm8